Attenuated bacterial vaccines Live attenuated bacterial vaccines for the prevention and eradication of multiresistant infections

  • Edition: 2016
  • Research center: Fundación Profesor Novoa Santos
  • Scientific Area: Pharmacology
  • Business area: Therapeutic
  • Status: In development
  • Contact: German.Bou.Arevalo@sergas.es

Platform for generating effective live bacterial vaccines composed of attenuated strains. It will focus on the development of effective vaccines against nosocomial infections (NIs) and other health-care associated infections (HAIs), which are multidrug-resistant (MDR). Their impact implies prolonged hospital stay, long-term disability, and deaths. In addition, S.aureus is the main etiological pathogen for bovine mastitis. Other animal bacterial pathogens can benefit for our system. In all cases, there is a clear need for novel effective strategies to combat these infectious diseases.

Goals

  • To develop a universal platform for bacterial attenuation to generate prophylactic live vaccines. This approach can target virtually any type of bacteria.
 

See project infographic:

Infographic

Problem to Solve

Antibiotic-resistant bacteria cause substantial healthcare expenditures, unnecessary deaths and ecomonic loss in milk and food production worldwide. Accordingly, the WHO has highlighted the loss of effective antibiotics as a crucial problem that will undermine our ability to properly fight infectious diseases.

Innovation

The strategy represents a pioneering approach for virulence attenuation that would facilitate vaccine production. The platform entails a simple creation of auxotrophy to convert any bacteria into an attenuated microorganism that can be used as a vaccine.

Level of Innovation

The proposed approach has added value with respect to classical vaccines, i.e. live-attenuated or inactivated. The platform developed here include whole-cell presentation of antigens, rapid and strong immune response without extracting and purifying proteins, with no safety concerns on the possibility of complete inactivation. In addition, the pilot vaccine prototypes already developed for anti-P.aeruginosa, anti-A. Baumannii, anti-S. aureus and anti-K. pneumoniae represent a novel and realistic approach to tackle NIs, NAIs, community-acquiered infections and cattle mastitis.

Team

Director. Head of the Microbiology Department

German Bou Arevalo

CHUC - University Hospital A Coruña

Ph.D

M. M. Póvoa

CHUC - University Hospital A Coruña

Ph.D.

P. García

CHUC - University Hospital A Coruña

Ph.D.

M. Moscoso

CHUC - University Hospital A Coruña

Partners

Obra Social
Caixa Capital Risc